PTN

PALATIN TECH
AMEX

Real-time Quotes | Nasdaq Last Sale

0.4184
+0.0015
+0.36%
After Hours: 0.4100 -0.0084 -2.01% 17:58 04/03 EDT
OPEN
0.4300
PREV CLOSE
0.4169
HIGH
0.4300
LOW
0.3900
VOLUME
772.43K
TURNOVER
--
52 WEEK HIGH
1.780
52 WEEK LOW
0.3550
MARKET CAP
95.91M
P/E (TTM)
2.999
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTN stock price target is 2.167 with a high estimate of 3.000 and a low estimate of 1.500.

EPS

PTN News

More
  • Does Palatin Technologies, Inc.'s (NYSEMKT:PTN) CEO Salary Compare Well With Others?
  • Simply Wall St. · 6d ago
  • Analysts: These 3 “Strong Buy” Penny Stocks Could Gain Over 200%
  • TipRanks · 03/03 17:56
  • Introducing Palatin Technologies (NYSEMKT:PTN), A Stock That Climbed 69% In The Last Three Years
  • Simply Wall St. · 02/21 15:22
  • Mid-stage study underway evaluating Palatin's PL9643
  • Seeking Alpha - Article · 02/19 17:08

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About PTN

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.
More

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.